Northern Trust Corp Has $489.32 Million Holdings in Agilent Technologies, Inc. $A

Key Points

• Northern Trust Corp reduced its stake in Agilent Technologies by 0.2%, holding approximately 1.47% of the company worth $489 million.
• Several institutional investors increased their positions in Agilent, with Mirae Asset Global Investments growing its holdings by 13.5% during the first quarter.
• Agilent Technologies announced a quarterly dividend of $0.248, which reflects an annualized yield of 0.8%, and reported a revenue increase of 6.0% year-over-year in its latest earnings results.

Northern Trust Corp cut its stake in Agilent Technologies, Inc. (NYSE:A - Free Report) by 0.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,182,915 shares of the medical research company's stock after selling 9,875 shares during the period. Northern Trust Corp owned 1.47% of Agilent Technologies worth $489,317,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Whipplewood Advisors LLC raised its stake in shares of Agilent Technologies by 286.2% in the first quarter. Whipplewood Advisors LLC now owns 251 shares of the medical research company's stock worth $29,000 after acquiring an additional 186 shares during the last quarter. Sunbelt Securities Inc. raised its stake in shares of Agilent Technologies by 640.0% in the fourth quarter. Sunbelt Securities Inc. now owns 222 shares of the medical research company's stock worth $30,000 after acquiring an additional 192 shares during the last quarter. Stone House Investment Management LLC bought a new position in shares of Agilent Technologies in the first quarter worth about $30,000. Opal Wealth Advisors LLC bought a new position in shares of Agilent Technologies in the first quarter worth about $31,000. Finally, Wood Tarver Financial Group LLC bought a new position in shares of Agilent Technologies in the fourth quarter worth about $34,000.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on A shares. Barclays boosted their target price on shares of Agilent Technologies from $115.00 to $125.00 and gave the stock an "equal weight" rating in a research note on Tuesday, June 24th. Wall Street Zen upgraded shares of Agilent Technologies from a "hold" rating to a "buy" rating in a research report on Saturday, June 28th. UBS Group lowered their price target on shares of Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating for the company in a research report on Thursday, May 29th. Evercore ISI lifted their price target on shares of Agilent Technologies from $125.00 to $130.00 and gave the stock an "in-line" rating in a research report on Tuesday, July 8th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating for the company in a research report on Thursday, May 29th. Seven investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Agilent Technologies presently has an average rating of "Moderate Buy" and a consensus price target of $139.77.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of the company's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total transaction of $177,099.52. Following the sale, the chief executive officer directly owned 37,448 shares of the company's stock, valued at approximately $4,397,893.12. This represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Agilent Technologies Trading Down 1.6%

NYSE A traded down $1.9560 during trading on Monday, reaching $119.6740. 306,246 shares of the stock traded hands, compared to its average volume of 1,935,755. The firm has a market cap of $34.00 billion, a price-to-earnings ratio of 29.55, a price-to-earnings-growth ratio of 3.69 and a beta of 1.22. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $153.84. The company has a quick ratio of 1.60, a current ratio of 2.09 and a debt-to-equity ratio of 0.55. The stock's 50-day moving average price is $117.88 and its 200 day moving average price is $117.05.

Agilent Technologies (NYSE:A - Get Free Report) last released its quarterly earnings results on Wednesday, May 28th. The medical research company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.05. The company had revenue of $1.67 billion during the quarter, compared to analysts' expectations of $1.63 billion. Agilent Technologies had a net margin of 17.59% and a return on equity of 25.92%. The business's quarterly revenue was up 6.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.22 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.540-5.610 EPS. Q3 2025 guidance at 1.350-1.370 EPS. Analysts predict that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.